Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-cash Items: 2014-2024

Historic Non-cash Items for Coherus Oncology (CHRS) over the last 10 years, with Dec 2024 value amounting to $17.0 million.

  • Coherus Oncology's Non-cash Items fell 54.52% to $17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $17.0 million, marking a year-over-year decrease of 54.52%. This contributed to the annual value of $17.0 million for FY2024, which is 54.52% down from last year.
  • According to the latest figures from FY2024, Coherus Oncology's Non-cash Items is $17.0 million, which was down 54.52% from $37.4 million recorded in FY2023.
  • Over the past 5 years, Coherus Oncology's Non-cash Items peaked at $72.4 billion during FY2020, and registered a low of $17.0 million during FY2024.
  • Its 3-year average for Non-cash Items is $35.3 million, with a median of $37.4 million in 2023.
  • Per our database at Business Quant, Coherus Oncology's Non-cash Items soared by 77,115.39% in 2020 and then tumbled by 99.92% in 2021.
  • Coherus Oncology's Non-cash Items (Yearly) stood at $72.4 billion in 2020, then slumped by 99.92% to $61.4 million in 2021, then dropped by 16.12% to $51.5 million in 2022, then fell by 27.38% to $37.4 million in 2023, then crashed by 54.52% to $17.0 million in 2024.